Bank of America Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price objective lowered by investment analysts at Bank of America from $575.00 to $547.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an "underperform" rating on the biopharmaceutical company's stock. Bank of America's price target suggests a potential downside of 5.56% from the stock's previous close.

Other research analysts have also issued reports about the company. TD Cowen dropped their price objective on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research note on Tuesday, February 4th. Sanford C. Bernstein decreased their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. UBS Group cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their target price for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Citigroup dropped their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Finally, The Goldman Sachs Group decreased their target price on Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a "buy" rating on the stock in a report on Monday, April 14th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, nineteen have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $950.76.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded up $17.73 during trading hours on Thursday, reaching $579.22. The stock had a trading volume of 403,933 shares, compared to its average volume of 712,746. The company has a market cap of $63.32 billion, a price-to-earnings ratio of 15.14, a PEG ratio of 2.34 and a beta of 0.44. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The business's fifty day moving average is $643.90 and its two-hundred day moving average is $733.36. Regeneron Pharmaceuticals has a twelve month low of $525.99 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $11.86 earnings per share. As a group, research analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Pinney & Scofield Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $25,000. Rakuten Securities Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares in the last quarter. OFI Invest Asset Management acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $28,000. Avalon Trust Co acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $36,000. Finally, Crowley Wealth Management Inc. acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $36,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.